September 8, 2016

An Invasive Tumour Cell Subpopulation as a Therapeutic Target in Breast Cancer

My name is Tahereh Vakili (pictured right) and I’m
a Master’s student in the Department of Biochemistry a Western University. I work under the supervision of Dr. Eva Turley (pictured left), whose lab is located at London Health Sciences Centre’s London Regional Cancer Program. Dr. Turley’s lab is interested in the intricacies of the tumor microenvironment and particularly the role of hyaluronan (a molecule within the skin and other tissues) and its receptors RHAMM and CD44 in invasion and metastasis.

Breast tumors often display remarkable diversity of cells within. Some tumor cells may survive chemotherapy and possibly spread to form new tumors, which becomes a major impediment in treatment. My project focuses on a newly identified type of diversity in human breast cancer cell models based on hyaluronan binding. I investigate the sensitivity of these tumor cell subtypes to clinically routine chemotherapeutic regiments. To date, I’ve found that a high-binding subset is more chemoresistant than the low-binding cells. The findings of the study may be beneficial for designing new therapies that prevent tumor recurrence and prolong patient survival.

This past year has been a unique one for me. I enjoyed every single moment of being a new mom. Interestingly, my scientist brain saw raising a baby similar to conducting research, as I read literature on parenting and investigated a series of concepts with my baby. Now he has new learning opportunities spending time with children his age, and I am very excited to be return to the world of academic science.

Thank you to the BCSC for your trainee support!
– Tahereh Vakili, MSc Candidate
Pamela Greenaway-Kohlmeier Translational Breast Cancer Research Unit, London Health Sciences Centre

Innovation and Progress in 2026

From more targeted treatments to new ways of monitoring cancer and improving care, research is changing what is possible in breast cancer. Breast cancer research

INDUSTRY NEWS: The Next Chapter of Progress in HER2-Positive Early Breast Cancer

A significant step toward improving access to treatment for Canadians with HER2-positive early breast cancer was reached this month, following the completion of negotiations between

REAL Alliance National Clinical Recommendations Webinar

Breast cancer treatment is evolving faster than ever. New clinical evidence, emerging therapies, and advances in personalized care continue to reshape how patients are diagnosed,

Canadian Night at ESMO 2026

Breast Cancer Canada is pleased to once again bring the Canadian breast cancer community together during the European Society for Medical Oncology (ESMO) Congress. On Saturday,

Progress Through Research

Latest Research

Breast Cancer Canada donations fund life-saving research that directly impacts Canadian patients. That means better answers, bigger breakthroughs – and more personalized treatment for every breast cancer diagnosis.

Patient Tools

Our suite of digital tools are each designed to help individuals better manage their breast cancer journey through education, research and personalized insights, while also elevating the patient voice.

Patient Stories

Every breast cancer journey is unique, but together, these stories paint a powerful picture of progress. Through firsthand accounts from patients and survivors, we share stories that highlight the lived-experiences of breast cancer.

Fuel Progress

Progress happens when we invest in it. Canada is home to some of the world’s brightest minds in research. Together, we are advancing science, ensuring it leads to earlier detection, better treatments, and improved outcomes for patients across the country.